Kohlberg & Co. to merge Bemis® Healthcare Packaging with Nelipak
Category: #business  By Pankaj Singh  Date: 2019-08-10
  • share
  • Twitter
  • Facebook
  • LinkedIn

Kohlberg & Co. to merge Bemis® Healthcare Packaging with Nelipak

Bemis® will be incorporated with Nelipak and jointly operate under the Nelipak® Healthcare Packaging brand.

Nelipak® Corporation, Inc., a company that focuses on providing custom packaging for pharmaceutical and medical industries, recently announced that its parent firm Kohlberg & Company, L.L.C., an American private equity firm focused on leveraging buyout transactions, have finalized the acquisition of Bemis® Healthcare Packaging Europe from Amcor’s packaging business unit.

According to reports, Bemis® which is located in Derry (Northern Ireland, UK), Elsham (United Kingdom) and Clara (Ireland) which will be merged with Nelipak and the joint company will operate under the Nelipak® Healthcare Packaging brand.

Speaking on the move, Mike Kelly, President and CEO, Nelipak, said that the company is excited with its merger with Bemis® European Healthcare Packaging business, a firm with tremendous capabilities and workforce, and is delighted to welcome its team into Nelipak.

He said that their firm will leverage the unique capabilities of both firms to fulfill their customer’s requirement with world-class quality, innovative design and excellent service. He further claims that the merger would enhance Nelipak’s knowhow and provide flexible packaging options for their global customers.

According to Roger Prevot, Operating Partner, Kohlberg, the Bemis acquisition would offer new prospects to develop global scale and diversification across complementary product offerings. He claims that this merger would offer attractive opportunities for revenue growth from cross-selling and geographic expansions. Moreover, Mike and his team will become better equipped to serve the firm’s clients as a comprehensive partner for their packaging needs, he added.

For the uninitiated, Nelipak® Healthcare Packaging designs, develops and manufactures custom packaging products that offer superior protection for pharmaceuticals and medical devices. Its customers include some of the largest medical device and pharmaceutical companies in the world.

As for Kohlberg & Co., the company is located in Mount Kisco, New York and is a leading private equity firm that has managed to raise over $7.5 billion of committed equity capital.

Source Credit: http://www.nelipak.com/news/kohlberg-closes-on-acquisition-of-bemis-healthcare-packaging-europe-merges-with-nelipak/

 

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Pankaj Singh    

Pankaj Singh

With an experience as an insurance underwriter and a freelance writer under his belt, Pankaj Singh boasts of quite some expertise in the field of content creation. A qualified Post Graduate in Management, Pankaj has also completed a detailed course in Digital Marketin...

Read More

More News By Pankaj Singh

CoSara receives Indian regulatory authorization for its five IVDs
CoSara receives Indian regulatory authorization for its five IVDs
By Pankaj Singh

Co-Diagnostics, a renowned US-based molecular diagnostics company, having a patented, unique platform to develop diagnostics tests reportedly announced that CoSara Diagnostics, the company’s JV for production, has received regulatory clearance ...

U.S. government could issue new rules to block shipments to Huawei
U.S. government could issue new rules to block shipments to Huawei
By Pankaj Singh

  Trump administration had issued 75 licenses to allow Huawei suppliers to resume sales U.S. Commerce Department and other authorities focused on utilizing De minimis Rule The U.S. government is reportedly considering new policies to restr...

Cinda finalizes Phase I study of anti-PD-1 / HER2 bispecific antibody
Cinda finalizes Phase I study of anti-PD-1 / HER2 bispecific antibody
By Pankaj Singh

Cinda Biopharmaceutical, a startup that focuses on treating autoimmune and metabolic diseases, has recently announced the completion of its Phase I clinical study of human epidermal growth factor receptor-2 (HER2) and antibodies against programmed de...